HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Abemaciclib

HCID 46220502
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1231929-97-7
Standard SMILES
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1
InChIKey
UZWDCWONPYILKI-UHFFFAOYSA-N
Molecular formula
C27H32F2N8
Average molar mass
506.6 g/mol
Monoisotopic mass
506.27179938

Overview

Abemaciclib is a cell cycle inhibitor selective for CDK4/6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively.

Names & identifiers

Preferred name
Abemaciclib
IUPAC
N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
English name
Abemaciclib
Molecular formula
C27H32F2N8
Molecular weight
506.59

Names & synonyms

Abemaciclib1231929-97-7LY2835219VerzenioLY-2835219VerzeniosN-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine60UAB198HKN-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amineLY 2835219LY2835210LY-2835210
Show more names
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamineAbemaciclib (LY2835219)CS-814AbexiliabecileeAbemaciclib D7Abemaciclib D10Abemaciclib INN
2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)pyrimidin-2-yl)amineN-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazol-6-yl]pyrimidin-2-amineabemaciclibumN-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo(d)imidazol-6-yl)pyrimidin-2-amineN-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazol-6-yl)pyrimidin-2-amineN-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine

Properties

Computed structural properties

XLogP
3.8
Topological polar surface area
75 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
9
Rotatable bonds
7
Heavy atoms
37
Formal charge
0
Complexity
723

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents

Pharmaceuticals -> Listed in ZINC15

Human Drugs · 4 items

Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physicochemical properties

Boiling point
689.3 · 689.3±65.0 °C(Predicted)
Density
1.32 · 1.32±0.1 g/cm3(Predicted)
storage temp.
4 °C, · 4°C, protect from light
solubility
2 O; · insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming
form
solid
pka
7.69 · 7.69±0.10(Predicted)
color
Off-white to yellow

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 20% (1 of 5) of reports.

Danger

H360 (60%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesRepr. 1B (60%)

Toxicology

Hepatotoxicity · 1 item

In the large clinical trials, adverse events were common and led to dose reductions in up to one-half of patients and discontinuation in 9%. In preregistration clinical trials, ALT elevations occurred in 31% to 41% of abemaciclib treated subjects which were above 5 times the ULN in 3% to 5%. In one study, several recipients developed clinically apparent liver injury with jaundice and one recipient died of hepatic failure, but these outcomes were considered to be unrelated to abemaciclib therapy. Thus, there were no cases of clinically apparent liver injury that could be attributed to abemaciclib therapy during prelicensure studies. Since the approval and more widescale use of abemaciclib, there have been several published reports of its hepatotoxicity. Most reports of liver injury from abemaciclib are marked by prominent serum aminotransferase elevations (5 to 20 times ULN) with minimal bilirubin elevations and few symptoms arising 1 to 3 months after initiation of therapy, and with rapid resolution upon stopping abemaciclib. In several cases there was rapid recurrence on restarting, but subsequent tolerance without serum enzyme elevations upon switching to other cyclin-dependent kinase inhibitors such as palbociclib or ribociclib. Isolated cases of liver injury with jaundice and severe outcomes including fatalities attributed to abemaciclib have been reported but are rare.

Chemistry & industry

Pharmacology

ATC Code · 2 items

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein Binding · 1 item

According to in vitro models using animal brain tissues, the protein binding of abemaciclib is approximately 95-98%. While abemaciclib demonstrated *in vitro* binding to serum albumin, alpha-1-acid glycoprotein and other human plasma proteins in a concentration-depedent manner, its major metabolites are also shown to bind to plasms proteins as well. The approximate bound fractions of M2, M18 and M20 are 93.4%, 96.8% and 97.8%, respectively.

Pharmacodynamics · 1 item

In combination with fulvestrant, the progression-free survival for patients with HR-positive, HER2-negative breast cancer was 16.4 months compared to 9.3 months for patients taking a placebo with fulvestrant. As a monotherapy, 19.7% of patients taking abemaciclib achieved complete or partial shrinkage of their tumors for a median 8.6 months after treatment. Abemaciclib induces cell cycle arrest and exerts an antitumor activity in human tumor xenograft models. In patient investigations and a healthy volunteer study, abemaciclib is not shown to induce any clinically significant changes in the QTc interval.

Mechanism of Action · 1 item

Regulation of cell cycle is crucial in maintaining proper cell growth; dysregulated cell cycle signalling pathway is a key component in inducing hyperproliferation of cells and tumor formation in various cancers. G1 to S phase cell cycle progression, or transition through the G1 restriction point (R), is promoted by the retinoblastoma tumor suppressor protein (Rb)-mediated pathway. Activation of Rb-mediated pathway requires the interaction of Cyclin-dependent kinases (CDK) 4 and 6 with D-type cyclins, which drives the formation of active CDK4/CDK6 and subsequent phosphorylation of Rb. Rb is a tumor suppressant protein that inhibits proliferation through binding to and suppressing the activity of the E2F family of transcription factors. However, phosphorylation of Rb relieves suppression of E2F to allow expression of genes required for passage through the restriction point. This leads to increased expression of downstream signalling molecules and activity of protein kinases that promote the cell cycle progression and initiation of DNA replication. Phosphorylation of Rb and other proteins by CDK4/6 additionally leads to transcription of genes involved in cell cycle-independent activities including signal transduction, DNA repair transcriptional control, and mRNA processing. Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells. Unlike other CDK inhibitors such as [DB09073] and [DB11730], abemaciclib exhibits greater selectivity for CDK4 compared to CDK6.

Related reactions

2 records
New reaction record
HRID 299995 reaction equation
HRID 299995As reactant
HRID 2264366 reaction equation
HRID 2264366As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
1231929-97-7
PubChem CID
46220502
DTXSID
DTXSID20673119
ChEMBL
CHEMBL3301610
ChEBI
CHEBI:233362
UNII
60UAB198HK
EC Number
806-670-8
Nikkaji
J3.307.988E
InChIKey
UZWDCWONPYILKI-UHFFFAOYSA-N
SMILES
C1(NC2=NC=C(CN3CCN(CC)CC3)C=C2)=NC=C(F)C(C2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1
FDA UNII
60 UAB198HK · 60UAB198HK
NCI Dictionary of Cancer Terms
abemaciclib
NCI Drug Dictionary
abemaciclib
ATC code
1 EF03 · L01EF03
Comptox DTXSID
20673119 · DTXSID20673119
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
373 · H373-H360-H410
Precautionary statements
273 · P273-P391-P501-P260-P314-P501
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Abemaciclib

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Danger
Symbol(GHS)
GHS08
Hazard statements
H373-H360-H410
Precautionary statements
P273-P391-P501-P260-P314-P501
Biological Half-LifeThe mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).
Metabolism/Metabolites · 1 item

Abemaciclib mainly undergoes hepatic metabolism mediated by CYP3A4. The major metabolite formed is N-desethylabemaciclib (M2), while other metabolites hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1) are also formed. M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively.

FDA Pharmacological Classification · 6 items

60UAB198HK

ABEMACICLIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Kinase Inhibitors

Abemaciclib is a Kinase Inhibitor. The mechanism of action of abemaciclib is as a Kinase Inhibitor.

ABEMACICLIB

Absorption, Distribution and Excretion · 4 items

The plasma concentration of the drug increases in a dose-proportional manner. Following a single oral dose administration of 200 mg abemaciclib, the mean peak plasma concentration (Cmax) of 158 ng/mL is reached after 6 hours. The median time to reach maximum plasma concentration (Tmax) ranges from 4-6 hours following an oral administration of abemaciclib over a range of 50–275 mg, but may range up to 24 hours. The absolute bioavailability of the drug is reported to be 45%.

Following a single oral dose of 150mg radiolabeled abemaciclib, approximately 81% of the total dose was recovered in feces while 3% of the dose was detected in urine. The majority of the drug is exceted as metabolites.

The geometric mean systemic volume of distribution is approximately 690.3 L (49% CV).

The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV).

Applications

UsesAbemaciclib is a potent and selective inhibitor of cyclin-dependent kinases, CDK4 and CDK6, as a method to inhibit the proliferation of cancer cells.

Upstream & downstream products

Upstream raw materials

EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-4-Bromo-2,6-difluoroaniline2-Bromopyridine-5-carbaldehydePiperazine, 1-[(6-broMo-3-pyridinyl)Methyl]-4-ethyl-N-Isopropylacetamide1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)-1H-BenziMidazole, 4-fluoro-2-Methyl-1-(1-Methylethyl)-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-4-Amino-3,5-difluoroacetophenone5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole1-Ethylpiperazine2,6-Difluoroaniline